Aurora Cannabis abandons recreational cannabis to focus entirely on medical cannabis

Canadian cannabis producer Aurora Cannabis announced a major strategic change: the company is withdrawing from the cannabis for adults to focus exclusively on opportunities in the medical marijuana worldwide in search of more stable margins and long-term growth.

A strategic pivot towards higher-margin medical markets

According to Simona King, the company's CFO, she believes that the markets of the medical marijuana offer greater profitability than the recreational segments. While much of the North American cannabis industry has focused on expanding the legalization of recreational use, Aurora believes that the medical model offers greater stability.

Ms King, who previously worked in the pharmaceuticals sector, pointed out that the national medical cannabis programs often operate in a similar way to pharmaceutical supply chains. These systems typically include strict distribution channels, standardized product requirements and physician oversight.

As a result of this structure, medical markets may also be less vulnerable to strong growth. price compression which affects recreational cannabis in countries such as Canada and several American states. In the highly competitive adult markets, oversupply and aggressive competition between retailers have driven prices down, eroding producers' margins.

Aurora's management therefore considers that regulated medical settings offer a more predictable business environment.

Medical cannabis already dominates Aurora's revenues

The company financial results illustrate the scale of this transition. In its third fiscal quarter 2025, Aurora reported sales of 94.2 million Canadian dollars (around 65 million euros), an increase of 7% over the previous year.

The medical cannabis segment accounted for 81% of Aurora's total sales and an even larger share, 95%, of adjusted gross margin.

When Miguel Martin becomes CEO in 2020, The company had already begun to restructure its operations and increase its focus on medical markets and international exports. In 2021, Aurora also appointed Theresa Firestone to its Board of Directors, known for having helped launch the medical cannabis program at Shoppers Drug Mart, one of Canada's leading pharmacy chains.

Europe emerges as a key growth market

Aurora's strategy increasingly revolves around the expansion of the medical cannabis in Europe.

In order to strengthen its position in these markets, Aurora was awarded the European Union Good Manufacturing Practice (EU-GMP) for one of its installations in Ontario. This certification is essential for exporting cannabis-based products to European medical markets, where regulatory requirements are very similar to those of the pharmaceutical industry.

Aurora is one of only three authorized producers to grow and process cannabis in Germany, Europe's largest medical cannabis market. Aurora also claims to be the first cannabis producer in Poland, another country where patient access has expanded in recent years.